Detalhe da pesquisa
1.
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.
Blood
; 141(6): 634-644, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36219880
2.
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
Br J Cancer
; 125(5): 687-698, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34140638
3.
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Breast Cancer Res
; 22(1): 87, 2020 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32787886
4.
BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics.
Haematologica
; 109(4): 1253-1258, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37881837
5.
The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Neuroendocrinology
; 106(1): 1-19, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-27871087
6.
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
Haematologica
; 105(3): e116-e120, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31320555
7.
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Proc Natl Acad Sci U S A
; 107(33): 14903-8, 2010 Aug 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-20668238
8.
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.
Clin Cancer Res
; 28(6): 1087-1097, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34921024
9.
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Clin Cancer Res
; 28(5): 870-881, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34862243
10.
Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
Cancer Res
; 81(11): 3079-3091, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33504557
11.
Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
Eur J Cancer
; 126: 93-103, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31927215
12.
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
Cancer Cell
; 38(6): 872-890.e6, 2020 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33217342
13.
A novel human protein of the maternal centriole is required for the final stages of cytokinesis and entry into S phase.
J Cell Biol
; 161(3): 535-45, 2003 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-12732615
14.
Therapeutic strategies for inhibiting oncogenic BRAF signaling.
Curr Opin Pharmacol
; 8(4): 419-26, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18644254
15.
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.
Sci Transl Med
; 11(505)2019 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31413145
16.
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
Leukemia
; 33(4): 905-917, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30214012
17.
Corrigendum to "Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma" [Eur J Cancer 126 (2020) 93-103].
Eur J Cancer
; 184: 199, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868971
18.
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.
Cancer Res
; 78(21): 6257-6267, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30135191
19.
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.
Elife
; 62017 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28425916
20.
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.
Cell Rep
; 21(7): 1953-1967, 2017 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29141225